Wikidoc news template
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
This is a template for creating your wikidoc new articles.
Month day, year By your name and title. [1]
Location of Trial/study: Treatment of in-stent restenosis (ISR) remains a clinical challenge for interventional cardiologists. Although clinical recurrence due to restenosis occurs in less than 5% of patients after drug-eluting stent (DES) placement, it may occur as a result of either focal tissue growth within the stent or at its margins. DES reimplantation is generally accepted as the treatment of choice for DES ISR, but it is not clear whether the same or a different DES should be used.
In the last issue of choose: Circulation
Journal of the American College of Cardiology
The American Journal of Cardiology
Cardiac Catheterization and Intervention
The Journal of Thrombolysis and Thrombosis
TCT MDCatheterization and Cardiovascular Intervention, Garg and colleagues from the Washington Hospital Center report the results of a cohort study in patients who underwent reimplantation of drug-eluting stent (DES) for the treatment of DES ISR. A total of 116 patients were included in the study, 53.4% of these patients were treated with a different DES than that which was originally implanted and 46.6% with the same DES.
All patients had clinical follow-up at 30 days, 6 months and 1 year. A major adverse cardiac event (MACE) was defined by death, Q-wave MI, and target vessel revascularization (TVR). By six months, TVR-MACE occurred in 14.5% of the patients treated with different DES and in 16.7% with the same DES (p=0.750); at 1 year, TVR-MACE developed in 32.6% of patients treated with a different DES and in 35% treated with the same DES (p=0.814). Irrespective of the type of DES used, the restenosis rates were considerably high (12.2% at 6 months and 28.8% at 1 year).
This study suggests that late outcomes are not affected by whether the same or different DES is used for the treatment of DES in-stent restenosis.
<biblio>
- ref1 pmid=17580367 This is free space so that you can describe the reference if you want
</biblio>
DO NOT FORGET TO CHANGE: THE PUBMED ID NUMBER AND THE LINK TO THE JOURNAL.
